Skip to main content

Cytokeratin 19 Antibody (KRT19/799) [Janelia Fluor® 669]

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-47945JF669

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-47945JF669

Key Product Details

Species Reactivity

Human

Applications

CyTOF-ready, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot

Label

Janelia Fluor 669

Antibody Source

Monoclonal Mouse IgG2a Lambda Clone # KRT19/799

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Recombinant human Cytokeratin 19 protein (Uniprot: P08727)

Localization

Cytoplasmic

Specificity

Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Marker

Pancreatic Stem Cell Marker

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2a Lambda

Applications for Cytokeratin 19 Antibody (KRT19/799) [Janelia Fluor® 669]

Application
Recommended Usage

CyTOF-ready

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Immunocytochemistry/ Immunofluorescence

Optimal dilutions of this antibody should be experimentally determined.

Immunofluorescence

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry-Paraffin

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: Cytokeratin 19

Cytokeratin 19 (also known as Keratin, type I cytoskeletal 19) belongs to the keratin family which consists of fibrous proteins that make up the framework of epithelial cells. Cytokeratin 19 plays a role in the organization of myofibers. This protein is known to have interactions with ZNF638, FANCG, FAM107A, KRT15 and EXOC8. Cytokeratin 19 has been studied in relation to several disorders and diseases including chordoma, adenoma, hamartoma, adenoiditis, carcinoma, and liver disease.

Alternate Names

CK19, EndoC, K19, Krt19

Gene Symbol

KRT19

Additional Cytokeratin 19 Products

Product Documents for Cytokeratin 19 Antibody (KRT19/799) [Janelia Fluor® 669]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Cytokeratin 19 Antibody (KRT19/799) [Janelia Fluor® 669]



Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...